Acambis' universal vaccine begins human clinical trials
Acambis is putting its universal vaccine approach to influenza to the test as it launches a Phase I trial for ACAM-FLU-A, a universal therapy for all type "A" strains of the influenza virus. Researchers are looking for both efficacy as well as safety data by around the end of the year. The vaccine has potential as a therapy for use against a pandemic flu as well as seasonal flu. Pandemics are typically triggered by an "A" strain flu while seasonal flus are both "A" and "B" strains.
- read the report on Acambis from Hemscott
Related Articles:
FDA panel endorses Acambis' smallpox vaccine. Report
Acambis restructures as sales rumors circulate. Report
Acambis announces new CEO. Report
Acambis researching single-shot flu solution. Report
Be the first to comment Rate it:
Comments
Post new comment
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight